KALY – Kali-Extracts, Inc. Publishes Cannabis Extract Lung Disease Treatment Study Preview

Kali Extracts

DALLAS, Feb. 05, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today published a preview of the recently announced long-term, pilot study on the treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates with cannabis extracts derived from Kali-Extracts patented cannabis extraction process. The study adds to the Kali-Extracts in vitro genomics study, previously announced, to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients. The World Health Organization estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.
The primate study was conducted by Professor Jeffry Osbourn, Ph.D., from the University of Kentucky and his Biomedical Science Research Group (BSRG). Professor Osbourn made the following statement in regard to the research: “We investigated the effects of a novel, new oral-delivered agent for the treatment of lung diseases like asthma, and inflammation of the lung airways, in research animals. To our surprise, the new [Kali-Extracts] supplement increased lung capacity by 2 to 3 times and increased the rate of breathing, returning lung function to normal. These large increases in lung function would likely lead to improved oxygen levels in the blood and increased breathing ability in these animals. Future experiments are planned to more closely identify the mechanisms of this improved overall lung function leading to greatly improved life styles and greater participation in daily activities for these patients.”
A final report on the primate study is coming in March.
Kali-Extracts, Inc. (“KALY”) is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies. KALY is utilizing is patented cannabis extraction process to develop numerous wellness products both internally and through partnerships. Similarly, KALY its patented cannabis extraction technology to develop pharmaceutical products internally and through partnerships.
KALY has licensed its extraction process to Puration, Inc. (USOTC: PURA) (“PURA”) for the production of beverages. With over $1 million in trailing twelve-month sales, PURA’s sales of EVERx CBD Sports Water are growing. KALY is now working with PURA to formulate a 25 MG CBD formula for a new CBD infused water product. Together, PURA and KALY have signed over a $1 million agreement to produce CBD infused water for Generex Biotechnology, Inc. (OTCQB: GNBT). The GNBT product is expected to be on shelves soon. The PURA and KALY agreement with GNBT is part of a larger agreement to explore potential pharmaceutical partnerships.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company’s actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.
Frederick Ferri
(214) 210-0459

MJ Canada

Related News